This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland
Menu

Bart Klein
Senior VP of Axiomer Technology at ProQR Therapeutics
Speaker

Profile

Bart Klein, SVP Head of Axiomer Strategy at ProQR Therapeutics

Bart Klein joined ProQR Therapeutics in 2014. He is a co-inventor of ProQR’s proprietary AxiomerTM RNA editing technology platform and led the R&D activities to develop it. In his current role, Bart focuses on pipeline building and partnerships. Prior to joining ProQR, Bart held leading roles in Intellectual Property in biotech and pharma. Bart has a scientific background in Chemical Biology, is a chartered Dutch and European patent attorney and an IMD alumnus.

Agenda Sessions

  • Developing RNA Editing As a New Class of Medicine: From Mechanism to Therapeutic Applications

    , 14:00
    View Session

At this event

Prev
Next
Alexander Kleinsmann, PhD
Director R&D, CMC Development
Bachem AG

See Bart at TIDES Europe: Oligonucleotide and Peptide Therapeutics